Skip to content
  • News
  • Compare
  • Capital
variis
  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Events
  • Funds
  • Press
variis

Longevity intelligence for Singapore and Australia. Sourced and evidence-graded.

Directories

  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Funds
  • Events

Read

  • Archive
  • Capital
  • Compare
  • Glossary

Markets

  • Singapore
  • Australia

variis

  • About
  • Editorial standards
  • AI transparency
  • Corrections
  • Press

Legal

  • Medical disclaimer
  • Privacy policy
  • Terms of service

AI-assisted reporting, human-reviewed. Every claim sourced and graded. Not medical advice.

© 2026 variis · Singapore · Australia

  1. Home
  2. Articles

Archive

Every story variis has published.

The complete record of variis coverage across Singapore and Australia. Filter by market or topic. Sourced and evidence-graded.

Market
SingaporeAustraliaSingapore and AustraliaGlobal
Topic
ScienceRegulatoryClinicalCapitalPublic marketsIndustryProtocolLifestyleOpinion
Clear filters
MarketAll
AllSingaporeAustraliaSingapore and AustraliaGlobal
TopicCapital
AllScienceRegulatoryClinicalCapitalPublic marketsIndustryProtocolLifestyleOpinion
Clear filters
Singapore and Australia · CapitalTwo rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Singapore and Australia · Capital

Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Across eighteen months, the region's longevity capital has taken three distinct shapes: a Melbourne clinic's seed to Series A climb, a Singapore drug discovery company's Hong Kong listing, and a five year commitment to build a flagship clinic from scratch. Together they sketch what type of longevity business Singapore and Australia capital is actually prepared to back.

Commercial4 min read29 Jun